PRECLINICAL STUDIES IN METABOLIC DISEASES
State-of-the-art in vivo models for metabolic diseases.
HOLISTIC APPROACHES TO PUSH YOUR METABOLIC DISEASE PIPELINE FORWARD
It is estimated that the productivity loss caused by Diabetes Mellitus (DM) alone is as high as $65 billion in the United States only. Diabetes is only one of the myriad metabolic diseases that still need better treatments if not cures. Certain studies postulate that certain metabolic diseases (notably diabetes, obesity and hypercholesterolemia) are early risk factors for sporadic forms of Parkinson’s and Alzherimer’s diseases.
We are not reciting these facts just to spiral down into the “comorbidities rabbit-hole”. We are reciting these facts as a reminder to ourselves, as a CRO, and to you, as potential cure-finders, that the next breakthrough will impact millions of lives. When the next breakthrough is one pipeline away, you’ll want to be working with the right CRO. A choice made easy when you speak with PharmaLegacy.
PharmaLegacy – Accelerating drug discovery
Committed to Quality
- Capacity to house over 20,000 rodents and large animals
- Electronically managed, traceable research data
- On-site capacity for up to 350 non-human primates, with off-site capacity for up to 30,000 Cynomolgus and Rhesus monkeys
- 24/7 access to PharmaLegacy representatives